189 related articles for article (PubMed ID: 38564060)
1. The transition of medication overuse status by acute medication categories in episodic or chronic migraine patients to non-overuse status after receiving anti-CGRP monoclonal antibodies: a systematic review and meta-analysis of phase 3 randomized control trial.
Sirilertmekasakul C; Panto A; Lekhalawan P; Panyarachun P; Jindasakchai P; Rattanawong W
Neurol Sci; 2024 Apr; ():. PubMed ID: 38564060
[TBL] [Abstract][Full Text] [Related]
2. Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache.
Marmura MJ; Diener HC; Cowan RP; Tepper SJ; Diamond ML; Starling AJ; Hirman J; Mehta L; Brevig T; Cady R
Headache; 2021 Oct; 61(9):1421-1431. PubMed ID: 34551130
[TBL] [Abstract][Full Text] [Related]
3. Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study.
Cowan RP; Marmura MJ; Diener HC; Starling AJ; Schim J; Hirman J; Brevig T; Cady R
J Headache Pain; 2022 Sep; 23(1):115. PubMed ID: 36068494
[TBL] [Abstract][Full Text] [Related]
4. Overview on effectiveness of erenumab, fremanezumab, and galcanezumab in reducing medication overuse headache in chronic migraine patients.
Curone M; Tullo V; Didier HA; Bussone G
Neurol Sci; 2022 Sep; 43(9):5759-5761. PubMed ID: 35836032
[TBL] [Abstract][Full Text] [Related]
5. Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months.
Caronna E; Gallardo VJ; Alpuente A; Torres-Ferrus M; Pozo-Rosich P
J Headache Pain; 2021 Oct; 22(1):120. PubMed ID: 34620085
[TBL] [Abstract][Full Text] [Related]
6. Early Effect of Calcitonin Gene-related Peptide Monoclonal Antibodies in Migraine with Medication Overuse: A Single-center Retrospective Study.
Ito Y; Mitsufuji T; Okada M; Fujita S; Yokoyama R; Kawasaki H; Yamamoto T
Intern Med; 2023 Dec; 62(23):3455-3460. PubMed ID: 37062749
[TBL] [Abstract][Full Text] [Related]
7. Therapies targeting CGRP signaling for medication overuse headache.
Koumprentziotis IA; Mitsikostas DD
Curr Opin Neurol; 2022 Jun; 35(3):353-359. PubMed ID: 35674079
[TBL] [Abstract][Full Text] [Related]
8. Management of medication overuse (MO) and medication overuse headache (MOH) S1 guideline.
Diener HC; Kropp P; Dresler T; Evers S; Förderreuther S; Gaul C; Holle-Lee D; May A; Niederberger U; Moll S; Schankin C; Lampl C
Neurol Res Pract; 2022 Aug; 4(1):37. PubMed ID: 36031642
[TBL] [Abstract][Full Text] [Related]
9. Prevention of medication overuse and medication overuse headache in patients with migraine: a randomized, controlled, parallel, allocation-blinded, multicenter, prospective trial using a mobile software application.
Diener HC; Donoghue S; Gaul C; Holle-Lee D; Jöckel KH; Mian A; Schröder B; Kühl T
Trials; 2022 May; 23(1):382. PubMed ID: 35546412
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2.
Diener HC; Marmura MJ; Tepper SJ; Cowan R; Starling AJ; Diamond ML; Hirman J; Mehta L; Brevig T; Sperling B; Cady R
Headache; 2021 Jan; 61(1):125-136. PubMed ID: 33314079
[TBL] [Abstract][Full Text] [Related]
11. Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials.
Tepper SJ; Ashina M; Reuter U; Hallström Y; Broessner G; Bonner JH; Picard H; Cheng S; Chou DE; Zhang F; Klatt J; Mikol DD
J Headache Pain; 2021 Jul; 22(1):81. PubMed ID: 34301173
[TBL] [Abstract][Full Text] [Related]
12. Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study.
Vernieri F; Brunelli N; Messina R; Costa CM; Colombo B; Torelli P; Quintana S; Cevoli S; Favoni V; d'Onofrio F; Egeo G; Rao R; Filippi M; Barbanti P; Altamura C
J Headache Pain; 2021 Dec; 22(1):154. PubMed ID: 34922444
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibodies for chronic migraine and medication overuse headache: A real-world study.
Krymchantowski AV; Jevoux C; Krymchantowski AG; Silva-Néto RP
Front Neurol; 2023; 14():1129439. PubMed ID: 36937507
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.
Schoenen J; Manise M; Nonis R; Gérard P; Timmermans G
Rev Neurol (Paris); 2020 Dec; 176(10):788-803. PubMed ID: 32758365
[TBL] [Abstract][Full Text] [Related]
15. Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis.
Overeem LH; Raffaelli B; Mecklenburg J; Kelderman T; Neeb L; Reuter U
CNS Drugs; 2021 Aug; 35(8):805-820. PubMed ID: 34272688
[TBL] [Abstract][Full Text] [Related]
16. Medication Overuse Headache, Chronic Migraine and Monoclonal Antibodies Anti-CGRP: A Real-World Study.
Krymchantowski A; Jevoux C; Krymchantowski AG; Silva-Néto RP
Clin Neuropharmacol; 2023 Sep-Oct 01; 46(5):181-185. PubMed ID: 37748000
[TBL] [Abstract][Full Text] [Related]
17. The burden of medication overuse headache and patterns of switching and discontinuation among triptan users: a systematic literature review.
Deighton AM; Harris LA; Johnston K; Hogan S; Quaranta LA; L'Italien G; Coric V
BMC Neurol; 2021 Nov; 21(1):425. PubMed ID: 34727873
[TBL] [Abstract][Full Text] [Related]
18. Is prednisone still a reasonable option in the treatment of withdrawal headache in patients with chronic migraine and medication overuse headache in the age of CGRP antibodies? A narrative review.
Kaltseis K; Hamann T; Gaul C; Broessner G
Headache; 2022 Nov; 62(10):1264-1271. PubMed ID: 36437611
[TBL] [Abstract][Full Text] [Related]
19. Randomized controlled studies evaluating Topiramate, Botulinum toxin type A, and mABs targeting CGRP in patients with chronic migraine and medication overuse headache: A systematic review and meta-analysis.
Giri S; Tronvik E; Linde M; Pedersen SA; Hagen K
Cephalalgia; 2023 Apr; 43(4):3331024231156922. PubMed ID: 36856015
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of eptinezumab in patients with chronic migraine and medication-overuse headache: a randomized, double-blind, placebo-controlled study.
Yu S; Zhou J; Luo G; Xiao Z; Ettrup A; Jansson G; Florea I; Ranc K; Pozo-Rosich P
BMC Neurol; 2023 Dec; 23(1):441. PubMed ID: 38102535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
